Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY13 | Q9BPV8 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3227020 | 0.76 | — | — | |
| SCHEMBL1131639 | 0.75 | L3MBTL1 (0.31) | — | |
| SCHEMBL15875166 | 0.75 | NFKB1 (0.30) | — | |
| SCHEMBL6995701 | 0.72 | — | — | |
| SCHEMBL5173458 | 0.72 | POLB (0.38) | MEN1KMT2AKDM4ETDP1MAPT | |
| SCHEMBL5171573 | 0.72 | KMT2A (0.35) | MEN1KMT2AMAPT | |
| SCHEMBL589814 | 0.72 | SMN1; SMN2 (0.39) | ALDH1A1ATMMAPTTSHR | |
| SCHEMBL1147539 | 0.71 | — | — | |
| SCHEMBL1184758 | 0.71 | — | — | |
| SCHEMBL3579803 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200061072-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CERENIS THERAPEUTICS HOLDING SA (FR) | 2020-02-27 | — | — | US | disclosed |
| US-10220040-B2 | Compounds, compositions and methods useful for cholesterol mobilization | CERENIS THERAPEUTICS HOLDING SA (FR) | 2019-03-05 | — | — | US | disclosed |
| US-20180064718-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | ABIONYX PHARMA (FR) | 2018-03-08 | — | — | US | disclosed |
| EP-3241833-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION | Cerenis Therapeutics Holding SA (FR) | 2017-11-08 | — | — | EP | disclosed |
| US-9757381-B2 | Compounds, compositions and methods useful for cholesterol mobilization | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-09-12 | — | — | US | disclosed |
| EP-2629776-B1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-08-16 | — | — | EP | disclosed |
| US-9713619-B2 | Compounds, compositions and methods useful for cholesterol mobilization | CERENIS THERAPEUTICS HOLDING SA (FR) | 2017-07-25 | — | — | US | disclosed |
| US-20160361318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CERENIS THERAPEUTICS HOLDING SA (FR) | 2016-12-15 | — | — | US | disclosed |
| US-20150344455-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-12-03 | — | — | US | disclosed |
| US-9085585-B2 | Compounds, compositions and methods useful for cholesterol mobilization | CERENIS THERAPEUTICS HOLDING SA (FR) | 2015-07-21 | — | — | US | disclosed |
| US-20130267554-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CERENIS THERAPEUTICS HOLDING SA (FR) | 2013-10-10 | — | — | US | disclosed |
| EP-2629776-A2 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION | Cerenis Therapeutics Holding SA (FR) | 2013-08-28 | — | — | EP | disclosed |
| US-8349833-B2 | Compounds, compositions and methods useful for cholesterol mobilisation | CERENIS THERAPEUTICS HOLDING SA (FR) | 2013-01-08 | — | — | US | disclosed |
| US-20120129856-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION | CERENIS THERAPEUTICS SA (FR) | 2012-05-24 | — | — | US | disclosed |
| WO-2012054535-A2 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION | CERENIS THERAPEUTICS SA (FR) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064718-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CETP, LIPA, NPC1L1 | P2RY13 4222/4885ALDH1A1 2270/4885MEN1 1198/4885 |
| US-10220040-B2 | Compounds, compositions and methods useful for cholesterol mobilization | CETP, LIPA, NPC1L1 | P2RY13 4222/4885ALDH1A1 2270/4885MEN1 1198/4885 |
| US-20120129856-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILISATION | CETP, NPC1L1, NPC1 | P2RY13 3726/4885ALDH1A1 2237/4885MEN1 806/4885 |
| US-20150344455-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CETP, LIPA, NPC1L1 | P2RY13 4222/4885ALDH1A1 2270/4885MEN1 1198/4885 |
| US-20130267554-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CETP, LIPA, NPC1L1 | P2RY13 4222/4885ALDH1A1 2270/4885MEN1 1198/4885 |
| US-20200061072-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CETP, LIPA, NPC1L1 | P2RY13 4222/4885ALDH1A1 2270/4885MEN1 1198/4885 |
| US-20160361318-A1 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION | CETP, LIPA, NPC1L1 | P2RY13 4222/4885ALDH1A1 2270/4885MEN1 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.